ABSTRACT Adriamycin (doxorubicin) was encapsulated in human erythrocytes by means of a dialysis technique involving transient hypotonic hemolysis followed by isotonic resealing. Up to 1.6 mg of the drug was entrapped per ml of packed erythrocytes, with the efficiency of encapsulation being 60-80%. In vitro incubation of the Adriamycin-loaded erythrocytes in autologous plasma was accompanied by progressive release of unaltered Adriamycin in the medium. The efflux was still evident after 50 hr. The metabolism of encapsulated Adriamycin was restricted to limited formation of the C-13 hydroxylated metabolite, adriamycinol, in the normal erythrocytes but not in erythrocytes from individuals deficient in glucose-6-phosphate dehydrogenase (D-glucose-6-phosphate: NADP+ 1-oxidoreductase, EC 1.1.1.49) activity. Reductive bioactivation of encapsulated Adriamycin to yield the corresponding aglycones was not observed in a variety of conditions. However, when NADPH ferredoxin reductase and ferredoxin, both purified from spinach leaves, were co-entrapped within erythrocytes and allowed to catalyze electron transfer to Adriamycin intracellularly under N2, a quantitative conversion to 7-deoxyadriamycin aglycone was obtained. Adriamycinloaded erythrocytes did not show any significant oxidative damage, except for a variable increase of methemoglobin, suggesting some redox cycling between native Adriamycin and its semiquinone radical. Encapsulation of Adriamycin in autologous human erythrocytes may represent a therapeutic strategy for the slow release in circulation of this antineoplastic drug in order to reduce or prevent its adverse effects and especially the delayed cardiotoxicity that limits its use in patients with neoplastic disease.
Adriamycin (doxorubicin) is an anthracycline antibiotic of wide use in antineoplastic chemotherapy because of its remarkable cytotoxicity toward several solid tumors (1) (2) (3) . Among the adverse effects it produces, delayed cardiotoxicity is certainly the most serious. Accordingly, total dosage of Adriamycin should never exceed 500 mg per m2 of body surface (2) , which is usually administered fractionally at 3-week intervals.
It has been reported (4) that cardiotoxicity is almost completely prevented by slow intravenous infusion because of significantly improved pharmacokinetics. However, such a way of administration is not practicable for routine treatment in daily hospital therapeutic schedules. Alternative systems, such as Adriamycin-encapsulating liposomes (5) or use of intravenous peristaltic pumps, seem not to be practically applicable.
Human and animal erythrocytes have been proposed and used as carrier vehicles for a number of chemicals to be disseminated in the circulatory system (6) (7) (8) . When hypotonic dialysis is used to achieve encapsulation, carrier erythrocytes have near normal in vivo survival (6) . Cytotoxic and antineoplastic drugs have also been entrapped in erythrocytes for targeting purposes (9) or to obtain slow release of therapeutic agents (10) . Recently, daunomycin (daunorubicin), a close analog of Adriamycin, has been entrapped within human erythrocytes but found to produce marked perturbation of the loaded erythrocytes (11) .
To check whether Adriamycin-loaded human erythrocytes are a potentially useful vehicle for time-programmed dissemination via the circulatory system, we investigated the encapsulation potential, the intraerythrocytic metabolism, and the efflux of unaltered Adriamycin by using dialysis-loaded erythrocytes. The results reported in this paper indicate that such therapeutic strategy holds promise on the basis of in vitro studies. In addition to showing the potential for encapsulation, these findings demonstrate (i) limited biotransformation of Adriamycin intracellularly (because of the absence of electron transferases in the mature erythrocyte), (ii) a slow release of the unmodified molecule to the medium, and (iii) an absence of significant erythrocyte damage as assessed by several metabolic parameters.
MATERIALS AND METHODS Materials. The following chemicals were kindly provided as gifts by F. Niccolis and V. Malatesta (Farmitalia): Adriamycin, adriamycinol (13-dihydroadriamycin), 7-deoxyadriamycin aglycone, 7-hydroxyadriamycin aglycone, 7-deoxyadriamycinol aglycone. Glucose 6-phosphate, NADP+, hypoxanthine, xanthine oxidase, reduced glutathione (GSH), and ATP were purchased from Sigma. D- [1- '4C]Glucose was obtained from the Radiochemical Centre. Ferredoxin:NADP+ oxidoreductase (EC 1.18.1.2) and ferredoxin, both purified from spinach leaves to homogeneity (12) , were kind gifts from B. Curti and G. Zanetti.
Blood Samples and Enzyme Assays. Blood samples were obtained after informed consent from normal subjects (both males and females) and from glucose-6-phosphate dehydrogenase (G6PD; D-glucose-6-phosphate:NADP+ 1-oxidoreductase, EC 1.1.1.49)-deficient hemizygous males, of Sardinian ancestry, who were asymptomatic and had the Mediterranean variety of G6PD deficiency (13) , as assessed by estimates of erythrocyte G6PD activity in the range of 0.8 to 7 international units x 10-3 (mIU) per g of Hb (14) . Heparin was used as anticoagulant and leukocytes and residual platelets were removed according to Beutler et al. (15) .
Assays of Ca2+-ATPase and of Na+/K+-ATPase activities were carried out as described (16) . Ferredoxin reductase activity was assayed according to Zanetti and Curti (12) . Calcium and potassium were determined by atomic absorption spectrophotometry as described (17) . GSH and ATP were estimated according to Beutler (18) . Methemoglobin was determined according to the procedure of Evelyn and Malloy (19) and thiobarbituric acid-reactive material according to the procedure of Stock and Dormandy (20 (21) . Osmotic fragility curves were determined according to Sprandel and Zollner (11) .
Dialysis Encapsulation. Encapsulation of Adriamycin, ferredoxin:NADP+ reductase, and ferredoxin within human erythrocytes was achieved by the hypotonic dialysis-isotonic resealing method (22) essentially according to the procedure of Ropars and coworkers (23, 24 .039 Encapsulation was carried out as described at a 2.5 mM concentration of Adriamycin in 0.9% NaCl. In the diffusion experiments, matched erythrocyte suspensions were incubated at a final hematocrit of 70% with 2.5 mM Adriamycin in 0.9o NaCl. Incubations were for 60 min at 37°C, and then the erythrocytes were extensively washed with 0.9% NaCl until complete removal of externally absorbed Adriamycin and hemolyzed by addition of 10 vol of H20. The membranes were washed 10 times with H20. Results are the average of five experiments.
Adriamycinol-i.e., the C-13 hydroxylated metabolite of Adriamycin-was formed to a small extent during the incubation period (see below). Its level in the supernatant was lower than the intracellular level, but both increased in parallel, implying that this metabolite is also released.
Metabolism of Entrapped Adriamycin Within Erythrocytes. The initial entrapment of Adriamycin was found to be the same with normal erythrocytes as with cells from subjects who had the Mediterranean variety ofG6PD deficiency-i.e., much lower levels of G6PD activity (0.8-7.0 mIU per g of Hb) than those detected in normal subjects (4.8-5.9 IU per g of Hb). This allowed the metabolism of entrapped Adriamycin to be compared in normal and in G6PD-deficient erythrocytes. As shown in Table 2 difference between normal and G6PD-deficient cells ( Table  2 ). The only clearly detectable metabolite under these conditions was adriamycinol, the levels of which were consistently lower in the G6PD-deficient than in the normal erythrocytes.
Mechanisms Mediating Intracellular Metabolism of Erythrocyte-Entrapped Adriamycin. The lower rate of formation of adriamycinol in the G6PD-deficient than in the normal erythrocytes (Table 2) , coupled with the effects on HMS activities and on GSH levels, implicates aldehyde reductase as the only enzyme involved in the erythrocyte metabolism of encapsulated Adriamycin (29) . Anthracycline biotransformation can also occur in animal cells via one-or twoelectron reduction of the molecule (30) (31) (32) . This reaction results in quinone methide formation and subsequent loss of the amino sugar moiety (33 (Table 3) . A strict requirement for this process to take place was availability of glucose to erythrocytes as a source of NADPH for ferredoxin reduction, which in turn enables reduction of Adriamycin.
Properties of the Adriamycin-Loaded Erythrocytes. Osmotic fragility curves of human erythrocytes following encapsulation of Adriamycin, although being consistent for progressive changes occurring during incubation, were not significantly altered as compared with native and with unloaded erythrocytes (Fig. 2) . A number of metabolic properties of the three matched erythrocyte populations-i.e., native, unloaded, and Adriamycin-loaded-incubated for 24 hr at 37°C, are reported in Table 4 . The only significant difference in the Adriamycin-containing erythrocytes was an apprecia- ble formation of methemoglobin, the extent of which was rather variable in different experiments. It is important to notice that the activities of Ca2+-ATPase and of Na+/K+-ATPase, known to be targets of oxidant damage in erythrocytes (16, 17, 36, 37) , were unimpaired: accordingly, intraerythrocytic levels of Ca2+ and K+ were completely normal. Hemolysis was negligible in the three erythrocyte populations. These findings suggest that the encapsulated drug is not capable of causing extensive oxidative damage. DISCUSSION Interaction of Adriamycin with human erythrocytes has been investigated by several researchers (25-28, 38, 39) , who described a number of oxidative effects upon in vitro incubation of both normal and G6PD-deficient erythrocytes with this drug. In our experiments, except for methemoglobin formation, oxidative damage was not apparent. This seems to indicate different patterns of interaction of the extracellularly added and of encapsulated Adriamycin with erythrocytes, as suggested by different levels and subcellular distribution achieved with the two experimental approaches. It is possible that time-dependent influx of Adriamycin might maintain or even enhance redox cycling processes that lead to oxidative damage, while rapid entrapment results in immediate accumulation of the drug in the membrane, followed by delayed gradient-directed release into the medium (40) . Such membrane involvement, however, does not affect Ca2+-ATPase and Na+/K+-ATPase perhaps because of the limited bioactivation of the drug within the apolar environment of the membrane. This view is supported by results showing complete stability of the ATPases upon incubation of erythrocyte ghosts with Adriamycin, while inactivation occurred following addition of hypoxanthine and xanthine oxidase to the system (data not shown).
Formation of methemoglobin is a salient feature, although variable in extent, of the Adriamycin-loaded erythrocytes.
Since oxygen is required for methemoglobin levels to be enhanced, the reaction mechanism is apparently interaction of Adriamycin with oxyhemoglobin, yielding both methemoglobin and the Adriamycin semiquinone (41) . This is expected to react with oxygen to regenerate free Adriamycin and superoxide. As postulated by Bates and Winterbourn (41) , superoxide dismutase would drain this two-step process, thereby accelerating methemoglobin formation yet removing the Adriamycin semiquinone efficiently and thus preventing conversion to the aglycone (33) . Aglycone formation can occur in Adriamycin-loaded erythrocytes, however, if the reduction rate is greatly enhanced by co-entrapping ferredoxin reductase and the cells are depleted of oxygen. Accordingly, the enhanced concentration of methemoglobin implies redox cycling of Adriamycin, although with <30% oxidation during a 24-hr incubation, the reaction is relatively slow. It is unlikely to represent a problem in vivo since Adriamycin efflux from the loaded cells would be considerably faster than during in vitro incubation and methemoglobin formation would be correspondingly less. The only other metabolic change observed was conversion to adriamycinol, catalyzed by aldehyde reductase and driven by the hexose monophosphate shunt. Again, this was slow and unlikely to be significant in vivo.
The sum of the findings in the present experiments support the concept of using Adriamycin-loaded erythrocytes as suitable vehicles for slow release of the drug to peripheral targets. The most important findings from this standpoint are (i) the high encapsulation potential, (ii) the limited extent of biotransformation of the entrapped Adriamycin because of lack of specific enzyme systems and of a favorable balance of redox reactions preventing extensive semiquinone formation, (iii) probably as a consequence of ii, the observed absence of cytotoxic oxidative effects within the loaded erythrocytes, (iv) the slow release of unaltered Adriamycin from loaded erythrocytes. Assessing the in vivo life-span of the Adriamycin-loaded erythrocytes in an animal model, and especially in the mouse, whose erythrocytes are similar to human cells as concerns susceptibility to encapsulation (6) , is an important prerequisite before clinical trials. Furthermore, the pharmacokinetics of Adriamycin in this new drug delivery system deserve elucidation, since low release of the drug in circulation might improve its antitumor activity while reducing adverse effects and especially cardiotoxicity (4).
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